Researchers report the first blinded, randomized, sham-controlled evidence that a procedure called duodenal mucosal resurfacing may offer a safe and lasting way to maintain weight loss without ongoing medication. The findings suggest it could help patients hold onto the benefits they achieved while taking drugs such as Ozempic or other GLP-1 therapies.

“As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term,” said lead author Shelby Sullivan, MD, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and professor of medicine, Dartmouth Geisel School of Medicine. “But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need. These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”

How the “Gut Reset” Procedure Works

Duodenal mucosal resurfacing is an investigational endoscopic treatment that uses controlled heat to remove damaged tissue from the inner lining of the duodenum, the first section of the small intestine just below the stomach. This process, which ablates (burns) the unhealthy mucosal layer, encourages the growth of new, healthier tissue.

The ongoing REMAIN-1 trial is designed to test whether this renewal of the intestinal lining can trigger a lasting metabolic reset, helping the body maintain weight loss after stopping medications like semaglutide or tirzepatide.

Trial Results Show Less Weight Regain

The current findings come from an early group of participants with six months of follow-up data. Among 45 people in this cohort, 29 received the resurfacing treatment while 16 underwent a sham procedure. All participants had previously lost at least 15% of their body weight using tirzepatide before stopping the drug.

On average, patients lost about 40 pounds while on GLP-1 therapy. Six months after discontinuing the medication, those in the control group regained significantly more weight. Participants who received the sham procedure regained about 40% more weight than those who underwent the actual treatment.

In addition, patients who had more extensive resurfacing regained only about 7 pounds and kept more than 80% of their weight loss. By comparison, the control group regained roughly twice as much. The gap between the two groups continued to widen from one to six months after the procedure, suggesting the benefits may persist and even strengthen over time.

“What’s particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response,” Dr. Sullivan said. “That gives us confidence that we’re targeting the right biology.”

Safety and Recovery

No serious complications were reported from either the device or the procedure. Recovery is relatively quick, with most patients returning to normal activities within about a day.

“Other than recovering from the general anesthesia, there isn’t much recovery time involved,” Dr. Sullivan said. “You can be back to your daily routine in about a day. Participants could not tell if they had the sham or real procedure because there are not a lot of symptoms after the procedure.”

Why the Gut Is Key to Weight Regulation

The treatment targets the small intestine, where many of the hormones affected by GLP-1 drugs are produced. Over time, diets high in fat and sugar can alter the lining of the duodenum, changing how the body processes food and regulates hormones. These changes can contribute to insulin resistance and metabolic disease.

By restoring a healthier mucosal layer, the procedure aims to reset how the body responds to food, helping stabilize metabolism at a lower body weight after stopping medications like Ozempic.

What Comes Next

Duodenal mucosal resurfacing is still considered investigational. The larger REMAIN-1 study includes more than 300 participants and is fully enrolled and randomized. Researchers expect topline six-month data from the pivotal cohort in early fourth quarter of 2026, followed by a planned marketing submission later that year.

Dr. Sullivan will present the findings from the study, “Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial — midpoint cohort results,” abstract 642, at 8:30 a.m. CDT, Monday, May 4.